CD8A and neoplasm: Kreiter and co-workers recently reported a list of mutation-derived, CT26-specific CD4+ and CD8+ T cell “neoepitopes” and showed that immunization with RNA vaccines encoding such neoepitopes elicited robust protection in BALB/c mice challenged with CT26 tumor cells (23).